Matrix metalloproteinases and their inhibitors in canine mammary tumors

Luca Aresu1*, Mery Giantin1, Emanuela Morello2, Marta Vascellari3, Massimo Castagnaro1, Rosa Lopparelli1, Vanessa Zancanella1, Anna Granato3, Spiridione Garbisa4, Arianna Aricò1, Alice Bradaschia4, Franco Mutinelli3 and Mauro Dacasto1

Abstract

Background: Malignant canine mammary tumors represent 50% of all neoplasms in female dogs. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are thought to be involved in tumor progression, and they are also associated with the reactive stroma, which provides structural and vascular support for tumor growth.

Results: MMP-2, MMP-9 and MT1-MMP were expressed at both the mRNA and protein levels in tumor samples. MMP-2 and MMP-9 immunohistochemical reactions were evident both in the epithelial tumor cells and in the stromal compartment to varying degrees; in particular, the intensity of the MMP-2 staining was stronger in the stromal fibroblasts close to epithelial tumor cells in simple carcinomas than in adenomas. These data were supported by gelatin-zymography; bands for the active form of MMP-2 were found in 94% of carcinoma samples, compared with 17% of benign tumor samples. The gene expression and immunohistochemical results for MT1-MMP were comparable to those for MMP-2. The immunoreactivity for MMP-13 and TIMP-2 was lower in carcinomas than in adenomas, confirming the mRNA data for MMP-13 and the other MMP inhibitors that were evaluated. The active form of MMP-9, but not the active form of MMP-2, was identified in the plasma of all of the tested dogs.

Conclusions: Our findings suggest that MMP-9, MMP-2 and MT1-MMP, which are synthesized by epithelial cancer cells and cancer-associated fibroblasts, play an important role in malignant canine mammary tumors. The reduction of MMP-13 and TIMP-2 could also be a significant step in malignant transformation. MMP-2 and MT1-MMP could be further evaluated as future biomarkers for predicting the progression and prognosis of canine mammary tumors.

Background

Mammary neoplasia is one of the most common tumors in dogs, and malignant types occur in approximately half of canine mammary tumors. Invasion and metastasis are typical features of carcinomas [1,2]. The physical process of tumor invasion involves cellular disengagement from the local microenvironment, followed by degradation of the surrounding matrix and cellular movement [3]. Invasion and metastasis of malignant tumor cells is a complex multistep process, in which the initial events are disruption of the extracellular matrix (ECM) and invasion of the basement membrane. In addition, fibroblasts in the stroma of cancerous tissue can promote the proliferation and invasion of carcinoma cells and induce angiogenesis via the secretion of several ECM molecules, proteases and cytokines [4,5]. This mechanism is highly organized and involves the selective action of a group of proteases that are active at neutral pH and can collectively degrade most, if not all, components of the ECM [6,7]. These proteases are known as matrix metalloproteinases (MMPs), and they hydrolyze the protein and proteoglycan components of the ECM. Under physiological conditions, MMPs are expressed by a variety of cells and tissues. MMPs are also involved in a number of pathological processes and are thought to be responsible for the accelerated ECM breakdown that
is associated with tumor invasion and metastasis [8]. Gelatinases are a subgroup within the MMP family and include MMP-2 and MMP-9. MMPs play the same role in dogs as in humans, controlling tumor invasion and progression in different tumors [9-14].

MMP-2 and MMP-9 are secreted in an inactive form, which is called a zymogen or a pro-MMP. Several types of inhibitors, called tissue inhibitors of MMPs (TIMPs), regulate MMP activity. TIMPs also function as MMP activators [15]. To exert their inhibiting or activating functions, TIMP-1 and TIMP-2 preferentially bind to MMP-9 or MMP-2, respectively [16,17]. The unbalanced activities of MMPs and TIMPs are involved in tumor progression [18]. Evaluation of the activities of TIMP-1, TIMP-2 and TIMP-3 in canine mammary tumor samples by reverse zymography has shown that low activity can be correlated with a malignant phenotype [14].

Membrane type 1 MMP (MT1-MMP) was the first MT-MMP to be identified as a major physiological activator of pro-MMP-2 in humans [9]. Studies of canine mammary tumors suggest that pro-MMP-2 activation requires the formation of a ternary complex that consists of the C-terminal domain of pro-MMP-2, TIMP-2 and MT1-MMP [19].

A new MMP inhibitor gene, called reversion-inducing cysteine-rich-protein with Kazal-motifs or RECK, was recently identified in dogs [20]; it was reported to be an endogenous MMP inhibitor and a membrane-anchored glycoprotein that has no structural homology with TIMPs but downregulates MMP-2, MMP-9 and MT1-MMP. RECK has been implicated in tumor progression [20].

The important role of another MMP family member, MMP-13, has been demonstrated in human cancer [21]. MMP-13 promotes tumor growth and progression by mediating ECM reorganization and regulating the biological activity of cytokines in skin squamous cell carcinoma [22], melanoma [23], breast cancer and colorectal cancer [24,25]. In veterinary medicine, reports of MMP-13 expression are only available for inflammatory and degenerative diseases [26,27].

The mRNA expression of MMP-2, MMP-9, TIMP-1, TIMP-2 and TIMP-3 has been extensively studied in vivo and in vitro in various human tumors [16,28-30]. In veterinary medicine, mRNA expression of these genes has been used to study canine neoplasia [12,20] and other diseases (e.g., meningitis-arteritis, chronic valvular disease, and arthritis [31-33]), but their expression in canine mammary tumors has not been specifically documented. Thanks to the sequencing of the entire dog genome, microarray technology has been used to characterize different canine mammary cell lines, progestin-induced canine mammary hyperplasia and spontaneous mammary tumors [34-37], but to our knowledge, no targeted gene expression profiling studies are available for spontaneous canine mammary tumors.

This report is the first study to consider MMP-2, MMP-9, MMP-13, MT1-MMP and TIMP-2 expression at both the mRNA and protein levels in canine mammary tumors including adenomas and carcinomas. The enzymatic activities of MMP-2 and MMP-9 were quantified by gelatin-zymography of the same homogenized tumor tissues and plasma from selected patients. Gene expression was evaluated also for TIMP-1, TIMP-3 and RECK. Moreover, the stromal compartments in these tumors were specifically evaluated.

Methods
Tissue sampling
Fresh tissue samples were obtained from 35 dogs that underwent surgery for mammary neoplasia. The dogs underwent surgery due to evident disease, and the explicit consent of the owner was obtained. Excised tumor lesions were immediately divided into aliquots and stored under diverse conditions for different analytical techniques. For RNA isolation, aliquots of approximately 100 mg were immersed in RNAlater® solution (Applied Biosystems, Foster City, CA) and stored at -20°C until use. For histological examination and immunohistochemistry, the tissue was formalin-fixed and paraffin-embedded. For gelatin-zymography, aliquots of up to 100 mg were frozen at -20°C until use.

Gene expression
Total RNA was isolated from control mammary glands, which were obtained from pathogen-free adult Beagles generously provided by GlaxoSmithKline Manufacturer S.p.A. (Verona, Italy) that had been used for other experimental purposes and 35 pathological samples using TRIZol® (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. The samples were purified with a classical phenol-chloroform extraction step. The total RNA concentration and quality were measured with a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE) and by denaturing gel electrophoresis.

First-strand cDNA was synthesized from total RNA using the High Capacity cDNA Transcription Kit according to the manufacturer’s protocol (Applied Biosystems, Foster City, CA).

The generated cDNA was used as the template for quantitative real-time RT-PCR (qRT-PCR) in a LightCycler 480 Instrument (Roche Diagnostics, Basel, Switzerland) using standard PCR conditions. The qRT-PCR reactions consisted of 1X LightCycler 480°® Probe Master (Roche Diagnostics, Basel, Switzerland), 300 or 600 nM forward and reverse primers (the primer combination and final concentrations were optimized during
2.01 software (San Diego, California, USA) was used, gene mRNA data was performed using a Spearman test. The correlation analysis of the target genes and a p value < 0.05 was considered significant. Finally, Grubbs’ test was used to identify outliers.

**Immunohistochemistry**
To analyze the expression of the MMP-2, MMP-9, MMP-13, MT1-MMP and TIMP-2 proteins by immunohistochemistry, contiguous 4 μm sections were cut from blocks of formalin-fixed, paraffin-embedded tissue, and the sections were placed on charged slides. After deparaffinization, the primary antibody incubation step for all antibodies was performed by an automated system (Ventana Medical Systems, Tucson, AZ). The pertinent antibody details are summarized in Table 2. The remainder of the staining procedure included incubation with a biotinylated anti-mouse secondary antibody, the diaminobenzidine substrate and a hematoxylin counterstain was performed using the Ventana ES automated immunohistochemistry system. Negative control slides were incubated with isotype-matched immunoglobulin in parallel with each staining batch to confirm the specificity of the antibodies. For each antibody, cases were semi-quantified for each protein-stained area. The intensity and the percentage of immunoassayed tumor cells were analyzed. Each slide was scanned with a 400× power objective in ten fields per slide, and the fields were selected for searching for protein-stained areas. A section was considered negative or positive according to the absence or presence of cytoplasmic staining. An intensity score of zero was given if no staining was detected, one if there was weak to moderate staining, two if moderate to strong staining was present, and three if strong staining was detected. A total score for each examined field was obtained by multiplying the intensity score by the percentage of immunoassayed cells. A final ratio was obtained after averaging the ten selected fields. An image analysis system that consisted of an Olympus BX51 microscope and software analysis (analySIS, Soft imaging system, Münster, Germany) was used. Furthermore, the immunoreactivity of each antibody was separately recorded for tumor and stromal cells in ten fields (400× power objective), and the final result was expressed as the average percentage from ten fields. For statistical analysis, dog tumors were subdivided into two groups: benign and malignant.

### Table 1 Primer sequences and UPL probes used for qRT-PCR amplification of selected target and reference genes.

| Genes       | Accession number | Primer sequence (5’-3’) | UPL probe |
|-------------|------------------|-------------------------|-----------|
| MMP-2       | [GenBank: XM_535300.2] | F: ggagcacggaagcatgtga | 29        |
|             |                   | R: atagtgtcacgtgccgttc  |           |
| MMP-9       | [GenBank: XM_536598.2] | F: cctcttctcgagaaacca  | 50        |
|             |                   | R: gcctggtgtatctttatcca |           |
| MMP-13      | [GenBank: XM_535300.2] | F: ggagcacggaagcatgtga | 29        |
|             |                   | R: atagtgtcacgtgccgttc  |           |
| MT1-MMP     | [GenBank: XM_536598.2] | F: cctcttctcgagaaacca  | 50        |
|             |                   | R: gcctggtgtatctttatcca |           |
| TIMP-1      | [GenBank: XM_531662.2] | F: ggagcacggaagcatgtga | 29        |
|             |                   | R: atagtgtcacgtgccgttc  |           |
| TIMP-2      | [GenBank: XM_531662.2] | F: ggagcacggaagcatgtga | 29        |
|             |                   | R: atagtgtcacgtgccgttc  |           |
| TIMP-3      | [GenBank: XM_531662.2] | F: ggagcacggaagcatgtga | 29        |
|             |                   | R: atagtgtcacgtgccgttc  |           |
| RECK        | [GenBank: XM_531662.2] | F: ggagcacggaagcatgtga | 29        |
|             |                   | R: atagtgtcacgtgccgttc  |           |
| CGI-119     | [GenBank: XM_535300.2] | F: ggagcacggaagcatgtga | 29        |
|             |                   | R: atagtgtcacgtgccgttc  |           |

F: forward; R: reverse

### Table 2 Antibody details.

| Antigen | Source     | Clone | Dilution | Manufacturer                  |
|---------|------------|-------|----------|-------------------------------|
| MMP-9   | Human      | MAB 3309 | 1:1000   | Chemicon (Millipore)          |
| MMP-2   | Human      | Ab-7   | 1:400    | Neomarkers, Fremont, USA      |
| TIMP-2  | Human      | MAB 3317 | 1:1000   | Chemicon (Millipore)          |
| MMP-13  | Human      | VIII A2 | 1:1000   | Millipore Co, Billerca, USA   |
| MT1-MMP | Human      |        | 1:200    | Millipore Co, Billerca, USA   |
Immunostaining score values for each protein were expressed as a median (range). The Mann-Whitney test was used to compare the immunostaining scores. Differences in percentages were calculated with the Chi-square test. The program SPSS 17.00 (SPSS Inc, Chicago, IL, USA) was used for all calculations.

Zymography
MMP-2 and MMP-9 activity was studied by zymography, which reveals the gelatinase activity of latent proenzymes (zymogens) and mature MMPs. The homogenized tissue was centrifuged at 1500 rpm for 10 min, and the protein concentration of the supernatant was measured. The sample protein concentration was adjusted to 1 mg/ml, and 5 μl was diluted 1:1 in sample buffer; the final 10 μl sample was subjected to electrophoresis on an 8% SDS-PAGE gel copolymerized with 0.1% gelatin. Following electrophoresis, the gel was incubated for 1 h at room temperature in a 2.5% Triton X-100 solution and then at 37°C for 16 h in 0.5 M Tris-HCl buffer, pH 7.4, with 10 mM CaCl₂. The gels were stained with 0.1% Coomassie Brilliant Blue R-250 and de-stained with 30% methanol and 10% acetic acid. Gelatinolytic activities were detected as unstained bands against the background of Coomassie-stained gelatin. Culture medium conditioned by A2058 melanoma cells was used as a control to identify the pro-MMP-9 gelatinolytic band, while conditioned media from HT1080 fibrosarcoma cells was used for the active forms of MMP-2 and MMP-9 and small amounts of the pro-MMP-2 [6]. The amount of MMP-9 in 20 μl of the A2058 melanoma cell-conditioned media was defined as 100 arbitrary units (a.u.). The MMP-2 activity in 20 μl of HT1080 fibrosarcoma cell-conditioned media was defined as 100 a.u. The bands were quantified using an image analyzer system that consisted of a GelDoc 2000 and Quantity One software (BioRad, Hercules, CA, USA).

Peripheral blood samples were collected from 14 dogs 24 h before surgery. The plasma was obtained by blood sample centrifugation and stored at -20°C, and 10 μl was used for analysis. The plasma concentrations of MMP-2 and MMP-9 were evaluated by gelatin-zymography. The gelatinolytic activity was defined as the arbitrary optical density value of the sample relative to the optical density value of the control plasma from healthy dogs.

Results
This study included 35 dogs with a median age of 9.9 years. Of the 35 tumors, 13 were simple adenomas, and 22 were simple carcinomas, according to the WHO classification system for canine mammary tumors [40].

Gene expression
The mRNA expression of MMP-2, MMP-9, MMP-13, MT1-MMP, TIMP-1, TIMP-2, TIMP-3 and RECK in mammary tumors and healthy mammary glands was investigated using a qRT-PCR approach. The overall results are reported in Table 3. All of the target genes were expressed in the control and tumor samples, with the exception of MMP-13, which was weakly expressed or not amplified in approximately half of the tumor samples (16 of 35 dogs). No statistically significant differences were observed for MMPs and inhibitors among the studied groups, particularly between benign and malignant tumors. Spearman correlation analysis was performed to identify potential relationships between MMPs and their preferential inhibitors at the transcriptional level and between MMP-2 and its well-known specific activator (MT1-MMP). Positive correlations were observed between MMP-2 and MT1-MMP (r = +0.52, p < 0.01), MMP-2 and TIMP-2 (r = +0.47, p < 0.01), MT1-MMP and TIMP-2 (r = +0.39, p < 0.05), and MMP-9 and TIMP-1 (r = +0.56, p < 0.001).

Immunohistochemistry
Immunohistochemical staining revealed that MMP-2 and MMP-9 were present in all of the tumors examined. In all samples, the two MMPs were strongly localized in the cytoplasm of the tumor epithelial cells (Figure 1a, b, c). There were significant differences in the immunohistochemical score values for these two markers in benign and malignant neoplasias (Table 4). An intense immunoreaction was especially evident for MMP-2 in carcinomas, while the difference in MMP-9 immunolabelling in adenomas and carcinomas was lower. The MT1-MMP protein was detected in 21 tumors, and its expression was higher in malignant tumors. Tissue leukocytes and eosinophils were occasionally found in close contact with the neoplastic epithelial cells in 18/35 tumors.

Table 3 mRNA expression of MMPs and inhibitors in control mammary glands and benign and malignant mammary tumors.

| Gene      | mRNA expression fold changes (arbitrary units) |
|-----------|-----------------------------------------------|
|           | Control mammary gland | Benign tumors | Malignant tumors |
| MMP-2     | 1.00 ± 0.46          | 1.01 ± 0.18   | 0.76 ± 0.12     |
| MMP-9     | 1.00 ± 0.30          | 9.95 ± 4.40   | 7.23 ± 1.58     |
| MMP-13    | 1.00 ± 0.28          | 2.08 ± 0.70   | 1.27 ± 0.25     |
| MT1-MMP   | 1.00 ± 0.24          | 13.26 ± 6.09  | 2.82 ± 0.64     |
| TIMP-1    | 1.00 ± 0.17          | 4.96 ± 1.27   | 3.97 ± 0.66     |
| TIMP-2    | 1.00 ± 0.34          | 0.49 ± 0.09   | 0.60 ± 0.09     |
| TIMP-3    | 1.00 ± 0.35          | 4.16 ± 1.62   | 2.38 ± 0.65     |
| RECK      | 1.00 ± 0.52          | 3.41 ± 1.77   | 0.51 ± 0.10     |

Data are expressed as the mean ± SEM.
Figure 1 Canine mammary tumors. (a) Epithelial tumor cells and stromal fibroblasts with intense MMP-2 immunopositivity in a carcinoma. (b) Epithelial tumor cells with weak MMP-2 immunopositivity in an adenoma. (c) Epithelial tumor cells and fibroblasts strongly MMP-9-immunolabelled in a carcinoma. (d) Epithelial tumor cells and stromal fibroblasts with intense MT1-MMP immunopositivity in a carcinoma. (e) Moderate TIMP-2 immunostaining in epithelial tumor cells in an adenoma. (f) TIMP-2 antibody-negative epithelial tumor cells in a carcinoma. (immunohistochemistry, 200×).
plasma cells stained positive for MMP-2 and MMP-9 as well as for MT1-MMP, which was considered a positive control. Immunohistochemical staining revealed that TIMP-2 and MMP-13 were more highly expressed in simple adenomas than in simple carcinomas (Figure 1e, f).

The magnitude of the immunohistochemical detection of MMP-2, MMP-9 and MT1-MMP varied in the fibroblasts of the stromal compartment. The staining intensity for MMP-2 and MT1-MMP (Figure 1d) was stronger in the fibroblasts closest to the epithelial tumor cells in the malignant tumors, while the fibroblasts that were immunolabelled by the antibodies for the two proteins were scattered in the adenomas (Table 5). The percentage of fibroblasts that were positive for MMP-9 staining was lower than the percentage that were positive for MMP-2 in carcinomas. The percentage of TIMP-2- and MMP-13-positive fibroblasts was higher in adenomas than in carcinomas. The immunohistochemical data are summarized in Tables 4 and 5.

Zymography

For each tumor sample, the active and inactive forms of MMP2 and MMP-9 were measured by their gelatinolytic activities (Figure 2). The activities of MMP-2 and MMP-9 were calculated in arbitrary units per 10 ng of protein. The pro-MMP-2 band was detected in all samples examined (adenoma and carcinoma). The activity of the carcinoma samples ranged between 16.7 and 59.9 units, while the activity of the adenoma samples ranged between 3.5 and 15.7 units. Bands for the active form of MMP-2 were found in 94% of the carcinoma samples and 17% of the benign tumor samples. In the simple carcinomas, the MMP-2 activity ranged between 47.4 and 87.5 units. The pro-MMP-9 band was detected in all samples examined by gelatin-zymography. The activity range of the carcinoma samples varied greatly (from 7.5 to 106.4 units), while the activity range of the twelve benign samples was between 20.5 and 41.2 units. Only eight carcinomas exhibited bands for the active form of MMP-9. The activity was similar among the samples, ranging from 34.3 to 40.3 units. No bands were observed for the active form of MMP-9 in adenomas.

The activities of both the pro- and activated forms of MMP-2 and MMP-9 were measured by gelatin-zymography of the plasma of fourteen dogs with mammary tumors and three healthy control dogs. A representative gel is shown in Figure 3. Regardless of the tumor type, the band for pro-MMP-9 was significantly more evident in the plasma of dogs with tumors than in healthy dogs. The activated form of MMP-9 was not observed in healthy dogs but was present in all of the dogs with tumors. Pro-MMP-2 was detectable in the plasma of all dogs with tumors and also in control dogs with no difference in the level of expression, and the MMP-2 activated form was not detectable in either case.

Discussion

In recent years, investigations of tumor growth have focused on the surrounding stroma in different tumors, which is important for cellular invasion, tumor growth and the epithelial mesenchymal transformation [41,42]. The engagement of the neoplasia with a ‘reactive stroma’ provides structural and vascular support for tumor growth and also leads to tissue reorganization and invasiveness [3]. MMPs play an important role in this mechanism by degrading the stromal connective tissue and basement membrane components. In addition, MMPs impact tumor cell behavior in vivo because of their ability to cleave growth factors, cell adhesion...
molecules, and chemokines. The proteolytic activity of MMPs can be regulated at different levels, including gene expression, the conversion of the zymogen to the active enzyme, and by the presence of specific inhibitors. Among MMPs, MMP-2 and MMP-9 have mainly been associated with malignant tumor progression and metastasis in both human and canine tumors [12,19,43]. In this study, the mRNA and protein levels of MMP-2, MMP-9, MMP-13, MT1-MMP and TIMP-2 in benign and malignant mammary tumors were thoroughly analyzed. We then analyzed TIMP-1, TIMP-3 and RECK mRNA expression and focused on the expression of different MMP proteins in stromal fibroblasts to identify a possible role in canine mammary tumors.

MMP-2 mRNA was expressed in all pathological samples, but no statistically significant differences were observed between benign and malignant tumors. On the contrary, at the protein level, immunohistochemistry identified higher MMP-2 expression in carcinomas; gelatin-zymography confirmed differences in MMP-2 production between adenomas and carcinomas ($p < 0.05$, data not shown). In particular, significant bands were observed for both the inactive and active forms of MMP-2 in simple carcinomas, while simple adenomas were characterized by minimal bands that corresponded to pro-MMP-2, suggesting that this enzyme is important during the infiltration process. Pro-MMP-2 may be converted to the active form during the infiltration process in malignancy; intense gelatinolytic activity has been described as necessary for malignant transformation [44]. These data are comparable to those from human studies. In human lung and gastric carcinomas, the MMP-2 activation ratio is enhanced; in canine tumor studies, higher MMP-2 and MMP-9 levels were observed in tumors than in inflammation, in malignant tumors than in benign tumors, in sarcomas than in

\[ \text{Figure 2 Zymographic assay of gelatinase activity in malignant (M) mammary neoplasia, in benign (B) mammary neoplasia and in the control (C). Bands corresponding to latent and active forms of MMP-9 and to latent and active forms of MMP-2 were observed in carcinomas (M), while bands corresponding to latent forms of MMP-9 and MMP-2 were observed in adenomas (B). HT1080 fibrosarcoma cells (C) were used as the control for pro-MMP-9, pro-MMP-2 and active form of MMP-2.} \]

\[ \text{Figure 3 Zymographic assay of gelatinase activity in pre-surgery plasma samples. (M = malignant mammary neoplasia, B = benign mammary neoplasia, C = control, N = normal dog). Bands corresponding to pro-MMP-2, pro-MMP-9 and active form of MMP-9 were observed in dogs with adenomas and carcinomas (B, M). Bands corresponding to pro-MMP-9 and pro-MMP-2 were observed in the control dog, and A2058 melanoma cells (C) were used as the control for active MMP-9.} \]
carcinomas and in the advancing edge of canine malignances than in the center of canine tumors [11]. In this study a band corresponding to active MMP-2 was observed in only two adenomas, and histological examination of these two samples showed an intense stromal reaction close to the tumor.

Activation of the zymogen form of MMP-2 is a cell-surface event that is mediated by members of the membrane-type subfamily of MMPs, and MT1-MMP is the first physiological activator of pro-MMP-2 [45]. In this study, the immunohistochemical data for MMP-2 and MT1-MMP were comparable for both adenomas and carcinomas. MT1-MMP was distributed similarly to MMP-2 in malignant tumors and was reduced in benign tumors. Despite the opposing results obtained for mRNA and protein expression in benign and malignant mammary tumors, a close relationship between MMP-2 and TIMP-1, TIMP-3 and RECK mRNA. The enzyme activity was analyzed by gelatin zymography. Pro-MMP-9 and pro-MMP-2 were significantly concentrated in the plasma of all of the dogs, and bands for the latent forms were present in both animals with adenoma and animals with carcinoma. Moreover, the active form of MMP-9 was present in the plasma of all of the dogs with tumors with no differences in concentration between benign and malignant neoplasias. These data could indicate that the plasma level of active MMP-9 is consistent with a protease activity that is due to the presence of an “ongoing disease,” and MMP-9 plasma levels may be a feasible method for detecting neoplastic growth in dogs in the future.

TIMP-1, TIMP-3 and RECK mRNA expression were also evaluated and no statistically significant differences were observed among the groups. Contrastting results are reported in literature: microarray studies in dogs have shown that TIMP-1 and TIMP-3 are inhibited in progesterin-induced canine hyperplasia relative to normal mammary glands [37]. Besides, a qRT-PCR study of RECK mRNA expression in various spontaneously developing canine tumors showed that expression levels were low in the majority of tumor tissues relative to normal tissues; however, in some neoplasias, RECK expression was higher than in the controls [47].

To exert its MMP inhibitory or activating role, TIMP-1 binds preferentially to MMP-9, and TIMP-2 binds to MMP-2 [16,17]. This relationship was confirmed in this study by the statistically significant correlations that were found between MMP-2 and TIMP-2, MMP-9 and TIMP-1 and MT1-MMP and TIMP-2 mRNA.

**Conclusion**

The observed discrepancy between the mRNA and protein data has also been described by other studies [49]. Enzyme accumulation that is not accompanied by an
increase in mRNA could be due to a feedback mechanism that shuts off mRNA expression after the secretion and/or binding of the protein. In addition, the samples used may not be representative [49]. Extracting and amplifying mRNA from cells obtained through the laser capture microdissection of the same formalin-fixed tissue that was used for immunohistochemistry might better clarify the mRNA/protein expression discrepancy observed in our study.

In conclusion, we have evaluated the involvement of MMP-2, MT1-MMP, MMP-9 and various TIMPs in canine mammary tumors, with an emphasis on the stromal compartment. The present work opens the possibility of developing new therapies and supports the use of the dog as an animal model in this field for studying the role of MMP-2 and MT1-MMP in the mechanism of cancer. MMPs may be target molecules of the switch mechanism that leads to the progression of carcinomas from adenomas.

Abbreviations
ECM: extracellular matrix; MMP: matrix metalloproteinases; MT1-MMP: membrane type 1 matrix metalloproteinase; qRT-PCR: quantitative real-time RT-PCR; UPL: Universal Probe Library; CGI-119: Transmembrane BAX inhibitor motif containing 4; GOLGA1: Golgin a 1; RECK: reversion-inducing cysteine-rich protein with Kazal-motifs.

Acknowledgements
This work was supported by a grant from Istituto Zooprofilattico Sperimentale delle Venezie (RC IZSVE 09/06) to M.D. and M.V.

Author details
1 Dipartimento di Sanità Pubblica, Patologia Comparata e Igiene Veterinaria, Facoltà di Medicina Veterinaria, Università degli Studi di Padova, Padova, Italy. 2 Dipartimento di Patologia Animale, Facoltà di Medicina Veterinaria, Università degli Studi di Torino, Italy. 3 Histopathology Department, Istituto Zooprofilattico Sperimentale delle Venezie, Viale dell’Università 10, 35020 Legnaro (PD), Italy. 4 Dipartimento di Scienze Biomediche Sperimentali, Università di Padova, viale Colombo 3, Padova, Italy.

Authors’ contributions
LA conceived of the study, participated in its design and coordination, performed the statistical analysis and drafted the manuscript. MG designed and performed the gene expression experiments, performed the statistical analysis and helped to draft the manuscript. RML and VZ participated in the qRT-PCR design and performance. AA, SG and AB participated in the analysis and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 22 October 2010 Accepted: 4 July 2011 Published: 4 July 2011

References
1. Yoshimura H, Michishita M, Ohkusu-Tsukada K, Takahashi K: Increased Presence of Stromal Myofibroblasts and Tenascin-C With Malignant Progression in Canine Mammary Tumors. Vet Pathol 2010.
2. Karayannopoulou M, Kaldymidou E, Constantinidis TC, Dessiris A: Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. J Comp Pathol 2005, 133(4):246-252.
3. Egeland M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2(13):161-174.
4. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
5. Li H, Fan X, Houghton J: Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 2007, 101(4):805-815.
6. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F: Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993, 53(22):5365-5369.
7. Liotta LA, Steeg PS, Sterrett-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64(2):327-336.
8. Montgomery AM, Mueller BM, Resfeld RA, Taylor SM, DeClerck YA: Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 1994, 54(20):5467-5473.
9. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993, 67(5):1126-1131.
10. Del Casar JM, Gonzalez LO, Alvarez E, Junquera S, Marin L, Gonzalez L, Borgera M, Vazquez J, Vizoso FJ: Comparative analysis and clinical value of the expression of metalloproteinases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat 2009, 116(1):39-52.
11. Loukopoulos P, Mungall BA, Straw RC, Thornton JR, Robinson WF: Matrix metalloproteinase-2 and -9 involvement in canine tumors. Vet Pathol 2003, 40(4):382-394.
12. Nakachi K, Yuniuki T, Okuda M, Ure S, Taura Y: Activity of matrix metalloproteinase-2 (MMP-2) in canine oronasal tumors. Res Vet Sci 2007, 82(2):271-279.
13. Hirayama K, Yokota H, Onai R, Kobayashi T, Kunsata T, Kihara K, Okamoto M, Sako T, Nakade T, Izumisawa Y, Taniyama H: Detection of matrix metalloproteinases in canine mammary tumours: analysis by immunohistochemistry and zymography. J Comp Path 2002, 127:249-256.
14. Kawai K, Uetsuka K, Doi K, Nakayama H: The activity of matrix metalloproteinase (MMPS) and tissue inhibitors of metalloproteinases (TIMPs) in mammary tumors of dogs and rats. J Vet Med Sci 2006, 68(2):105-111.
15. Lambert E, Dasse E, Haye B, Petitfere E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004, 51:187-198.
16. Sterrett-Stevenson WG, Krutzsch HC, Liotta LA: Tissue inhibitor of metalloproteinase (TIMP)-2: A new member of the metalloproteinase inhibitor family. J Biol Chem 1989, 264(29):17374-17378.
17. DeClerck YA, Yeon TD, Chan D, Shimada H, Langley KE: Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res 1991, 51(8):2151-2157.
18. Liotta LA, Sterrett-Stevenson WG, Steeg PS: Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest 1991, 9:543-551.
19. Papparella S, Restucci B, Paciello O, Maiolino P: Molecular cloning of canine membrane-anchored inhibitor of matrix metalloproteinase, RECK. J Vet Med Sci 2005, 67(4):385-391.
20. Freije JP, Diez-Itzu I, Balbin M, Sanchez LM, Blasco R, Tovilla J, Lopez-Otin C: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994, 269:16766-73.
21. Lederle W, Hartenstein B, Meides A, Kunzelmann H, Werb Z, Angel P, Mueller MM: MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Caringenogenesis 2010, 31(7):1175-84.
22. Meerjohann S, Hufnagel A, Wende E, Kleinschmidt MA, Wolf K, Friedl P, Gaubatz S, Schartl M: MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation. Mol Cancer 2010, 9:201.
24. Chang HJ, Yang MJ, Yang YH, Hou MF, Hsieh EJ, Lin SR: MMP13 is a potential new tumor marker for breast cancer diagnosis. Oncol Rep 2009, 22(5):1119-27.

25. Huang MY, Chang HJ, Chung FY, Yang MJ, Yang YH, Wang JY, Lin SR: MMP13 is a potential prognostic marker for colorectal cancer. Oncol Rep 2010, 24(5):1241-7.

26. House AK, Catchpole B, Gregory SP: Matrix metalloproteinase mRNA expression in canine anal furunculosis lesions. Vet Immunol Immunopathol 2007, 115(1-2):68-75.

27. Disatian S, Etipher EJ, Zimmerman S, Orton EC: Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation. J Heart Valve Dis 2008, 17(4):402-11.

28. Muller D, Wolf C, Abeckas J, Millon R, Engelmann A, Bronner G, Rauy N, Rio MC, Eber M, Methlin G: Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 1995, 55(1):165-169.

29. Urbanksi SJ, Edwards DR, Maitland A, Leco KJ, Watson A, Kossakowska AE: Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1993, 66(6):1188-1194.

30. Bhuvaramamurthy V, Kristiansen GO, Johannsen M, Loening SA, Schnorr D, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Menard S, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Menard S: Human breast tumors: gene expression profiles of ER-positive and -negative subgroups with different clinical outcome. J Pathol 2009, 213(2):269-277.

31. Schwartz M, Puff C, Stein VM, Baumgartner W, Tipold A: Marked MMP-2 transcriptional up-regulation in mononuclear leukocytes invading the subarchnoidal space in aseptic suppurative steroid-responsive meningitis-arthritis in dogs. Vet Immunol Immunopathol 2010, 133(2-4):199-206.

32. Aupperle H, Thieleben J, Kieler B, Marz I, Dinges G, Schoon HA, Schubert A: Expression of genes encoding matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in normal and diseased canine mitral valves. J Comp Pathol 2009, 140(4):271-277.

33. Mier P, Schaefer SL, Manley PA, Saven JP, Oldenhoff WE, Hao Z: Expression of immune response genes in the stifle joint of dogs with oligoarthritis and degenerative cranial cruciate ligament rupture. Vet Immunol Immunopathol 2007, 119(3-4):214-221.

34. Krol M, Pavlovski KM, Skierski J, Turowski P, Majewska A, Polanska J, Ukonski M, Morty RE, Motyl T: Transcriptional “portraits” of canine mammary cancer cell lines with various phenotypes. J Appl Genet 2010, 51(2):169-183.

35. Rao NAS, van Wolferen ME, van der Ham R, van Leenen D, Groot Aresu Junquera S, Merino AM, Garcia-Muniz JL: MMP13 is an independent prognostic marker of breast cancer. Br J Cancer 2007, 96(6):903-911.

36. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Selki M: Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 1995, 64(5):355-9.

37. Lambert K, Machein U, Machein MR, Conca W, Peter HH, Volk B: Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumours. J Neurol 1998, 245:429-437.

38. Greude L, Stetter-Stevenson WG, Wolf L, Wang J, Fukushima P, Mansoor A, Stetter-Stevenson M: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998, 102(11):2002-2010.

39. Takagi S, Kato Y, Asano K, Otsuki T, Bosnakovsky D, Hoshino Y, Okumura M, Kadosawa T, Fujirarta T: Matrix metalloproteinase inhibitor RECK expression in canine tumors. J Vet Med Sci 2005, 67(8):761-767.

40. Ring P, Johansson K, Hoyhyya M, Rubin K, Lindmark G: Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer—a predictor of tumour stage. Br J Cancer 1997, 76(6):805-811.

41. Caenazzo C, Onisto M, Sartor L, Scalaletta R, Giraldo A, Nitti D, Garabia S: Augmented membrane type 1 matrix metalloproteinase (MT1-MMP): MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis. Clin Cancer Res 1998, 4(19):2179-2186.